Patents by Inventor Nicholas C. K. Ling

Nicholas C. K. Ling has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5182375
    Abstract: Two follistatin proteins with inhibin-like activity were isolated from porcine follicular fluid using heparin-Sepharose affinity chromatography, followed by gel filtration on Sephacryl S-200 and then six steps of high-performance liquid chromatography. The larger protein has 315 residues and is believed to be glycosylated. The smaller protein is a 288-residue, C-terminally shortened version thereof. These proteins specifically inhibit basal secretion of FSH, but not of LH, in a rat anterior pituitary monolayer culture system. The half-maximal effective dose for both is 2.5-6.0 ng/ml. Human and rat follistatins exhibit very high homology with the porcine protein, with the human differing from porcine in only 4 residues out of 315 and with the rat differing from porcine in only 8 residues out of 315. Using the porcine amino acid sequence information, cDNA clones encoding these proteins were identified from a porcine ovarian cDNA library.
    Type: Grant
    Filed: May 31, 1991
    Date of Patent: January 26, 1993
    Assignee: The Salk Institute for Biological Studies
    Inventors: Nicholas C. K. Ling, Naoto Ueno, Shunichi Shimasaki, Frederick S. Esch, Shao-Yao Ying, Roger C. L. Guillemin
  • Patent number: 5041538
    Abstract: Two follistatin proteins with inhibin-like activity were isolated from porcine follicular fluid using heparin-Sepharose affinity chromatography, followed by gel filtration on Sephacryl S-200 and then six steps of high-performance liquid chromatography. Each isolated molecule is a monomer having a molecular weight of at least about 32,000 daltons. Microsequencing revealed the NH.sub.2 -terminal portions both to be Gly-Asn-Cys-Trp-Leu-Arg-Gln-Ala-Lys-Asn-Gly-Arg-Cys-Gln-Val-Leu. The larger protein has 315 residues and is believed to be glycosylated. The smaller protein is a 288-residue, C-terminally shortened version thereof. These proteins specifically inhibit basal secretion of FSH, but not of LH, in a rat anterior pituitary monolayer culture system. The Half-maximal effective dose for both is 2.5-6.0 ng/ml.
    Type: Grant
    Filed: July 26, 1988
    Date of Patent: August 20, 1991
    Assignee: The Salk Institute for Biological Studies
    Inventors: Nicholas C. K. Ling, Naoto Ueno, Shunichi Shimasaki, Frederick S. Esch, Shao-Yao Ying, Roger C. L. Guillemin